All In Biotech

Drug Trial Radar · NCT00661635

A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain

A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Laparoscopic Cholecystectomy Surgery

Last checked: Nov 20, 2026Latest source record: Apr 23, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

490

Actual

Start

Nov 2002

Primary completion

Not stated

Study completion Jul 2003

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the analgesic efficacy, general safety, and effects on health outcome measures and opioid-related symptoms of 2 valdecoxib dosing regimens compared with placebo in patients with moderate or severe pain following laparoscopic cholecystectomy surgery.

Conditions

  • Laparoscopic Cholecystectomy
  • Pain

Interventions

  • placeboDrug

    valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5

  • valdecoxibDrug

    valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.

  • valdecoxibDrug

    valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient's Global Evaluation of Study MedicationTime frame: Day 2 and Day 3
  2. Summed Pain Intensity (categorical) through 24 hours (SPI 24)Time frame: Day 2 and Day 3

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Daphne, Alabama

  • Pfizer Investigational Site

    Fairhope, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Sheffield, Alabama

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    Bakersfield, California

  • Pfizer Investigational Site

    Bakersfield, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Pasadena, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Jose, California

  • Pfizer Investigational Site

    Woodland, California

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Pensacola, Florida

  • Pfizer Investigational Site

    Blue Ridge, Georgia

  • Pfizer Investigational Site

    Marietta, Georgia

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Maywood, Illinois

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Shreveport, Louisiana

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Germantown, Maryland

  • Pfizer Investigational Site

    Rockville, Maryland

  • Pfizer Investigational Site

    Silver Spring, Maryland

  • Pfizer Investigational Site

    Jackson, Mississippi

  • Pfizer Investigational Site

    Durham, North Carolina

  • Pfizer Investigational Site

    Winston-Salem, North Carolina

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.